Palisade Bio
PALI | NASDAQ
$1.03
-$0.09 (-8.04%)
At close: Nov 16, 2026, 4:00 PM ET
$1.03
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-8.04%
(1D)No price chart data available for 1D timeframe.
Rating
50.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #268/1021 (Top 26%)
Key Statistics
Market Data
Market Cap $218.39M
1D Range
1.02 1.11
52W Range
1.01 2.80
Valuation (TTM)
PE -4.68
PB 1.94
EV/EBITDA -2.33
Valuation (NTM)
Forward PE N/A
Forward PEG 0.09
Price Target $4.50
Cash Flow
FCF Yield -12.1%
SBC Adj. FCF Yield -20.3%
SBC Impact -67.7%
Margins
Gross Margin 100.0%
Operating Margin -9625.4%
FCF Margin -5279.2%
Growth (CAGR)
Revenue 3Y | 5Y 26.0% |
50.0%
Dil EPS 3Y | 5Y 123.2% |
76.6%
FCF 3Y | 5Y -42.3% |
-16.9%
Returns
ROA -36.9%
ROE -35.6%
ROIC -42.7%
Financial Health
Net Cash
$113.61M
Current Ratio 20.16
Interest Coverage -48,127.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the ...
Sector Healthcare
Industry Biotechnology
Employees 14
IPO Date Mar 30, 2007
Website www.palisadebio.com
Fiscal Year January - December
Latest News
No news articles available yet.
Analyst Summary
# of Analysts
2
Consensus
Buy
Price Target
$4.50
Upside
+336.89%
Buy (2)
Hold (0)
Sell (0)
Add to Watchlist
Select watchlists to add or remove PALI